StreetInsider.com News Articles

UroGen Pharma (URGN) PT Raised to $50 at Oppenheimer

Thu, 16 Jul 2026 06:54:13 -0400

Oppenheimer analyst Leland Gershell raised the price target on UroGen Pharma (NASDAQ: URGN) to $50.00 (from $40.00) while maintaining a Outperform rating.

The analyst comments "We increase our sales estimates following recent conversations with management. We now project 2026-28E Zusduri sales of $210M, $448M, and $648M vs. $204M, $411M, and $595M, respectively. For the three remaining 2026 quarters to be reported, we now project Zus sales of $43.0M, $60.0M, and $78.0M vs. consensus (Visible Alpha) estimates of $38.5M, $48.1M, and $54.5M, respectively. We expect URGN to report 2Q26 financials in early August. We see continued outperformance following the recent run (shares

UroGen Pharma (URGN) PT Raised to $50 at Oppenheimer

Thu, 16 Jul 2026 06:54:13 -0400

Oppenheimer analyst Leland Gershell raised the price target on UroGen Pharma (NASDAQ: URGN) to $50.00 (from $40.00) while maintaining a Outperform rating.

H.C. Wainwright Reiterates Buy Rating on UroGen Pharma (URGN)

Thu, 16 Jul 2026 06:49:15 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $45.00 price target on UroGen Pharma (NASDAQ: URGN).

The analyst commented: "New patent claims may extend exclusivity until 2044, whereas our model assumes generic erosion starting in 2031. Yesterday, UroGen reported that it had received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application no. 18/784,354 entitled “Treatment of Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer (LG-IR-NMIBC) With a Thermally Gelling Pharmaceutical Composition Containing Mitomycin.” The allowed claims cover methods of treating patients with recurrent LG-IR-NMIBC without a transurethral resection of a bladder tumor (TURBT), supported by

UroGen receives U.S. patent notice covering bladder cancer treatment

Wed, 15 Jul 2026 08:00:27 -0400

UroGen Pharma Ltd. (Nasdaq: URGN) announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application covering methods of treating patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer without a surgical tumor removal procedure known as TURBT.

The allowed claims are supported by data from the ENVISION and ATLAS clinical trials. Once issued, the patent will carry an expiration date of July 2044.

The patent application, numbered 18/784,354, is titled "Treatment of Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer With a Thermally Gelling Pharmaceutical Composition Containing Mitomycin." The claims cover UroGen's approved product ZUSDURI (mitomycin)

UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103

Wed, 15 Jul 2026 08:00:00 -0400

PRINCETON, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application no. 18/784,354 entitled “Treatment of Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer With a Thermally Gelling Pharmaceutical Composition Containing Mitomycin.” The allowed claims cover methods of treating patients with recurrent, low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) without a transurethral resection of a bladder tumor (TURBT), supported by data from

UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103

Wed, 15 Jul 2026 08:00:00 -0400

Form 4 UroGen Pharma Ltd. For: Jul 09 Filed by: Schoenberg Mark

Fri, 10 Jul 2026 14:18:00 -0400

si-local-file:///var/storage/secattach/20260710/26756828.html

Form 4 UroGen Pharma Ltd. For: Jul 09 Filed by: Schoenberg Mark

Fri, 10 Jul 2026 14:18:00 -0400

si-local-file:///var/storage/secattach/20260710/26756828.html

Form 144 UroGen Pharma Ltd. Filed by: Schoenberg Mark

Thu, 09 Jul 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260709/26753456.html

Form 144 UroGen Pharma Ltd. Filed by: Schoenberg Mark

Thu, 09 Jul 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260709/26753456.html

H.C. Wainwright Reiterates Buy Rating on UroGen Pharma (URGN)

Thu, 09 Jul 2026 06:49:09 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $45.00 price target on UroGen Pharma (NASDAQ: URGN).

The analyst commented: "Yesterday, UroGen Pharma announced that the FDA had cleared the company's Investigational New Drug application (IND) for UGN-501, a next-generation oncolytic virus candidate. The IND clearance enables initiation of a planned Phase 1 study in patients with non-muscle invasive bladder cancer (NMIBC). The Phase 1 study is slated to start in 4Q26 and will evaluate the safety, tolerability, and feasibility of intravesical administration of UGN-501. NMIBC continues to present significant clinical challenges, particularly among patients whose disease recurs following standard

UroGen gets FDA IND clearance for bladder cancer virus therapy

Wed, 08 Jul 2026 08:02:17 -0400

UroGen Pharma Ltd. (Nasdaq: URGN) announced that the U.S. Food and Drug Administration cleared the company's Investigational New Drug application for UGN-501, an investigational oncolytic virus intended for the treatment of non-muscle invasive bladder cancer.

The clearance allows UroGen to proceed with a planned Phase 1 clinical study evaluating the safety, tolerability, and feasibility of intravesical administration of UGN-501. Patient enrollment is expected to begin in the fourth quarter of 2026.

UGN-501 is designed to selectively replicate within tumor cells, with the goal of producing direct tumor cell destruction alongside an anti-tumor immune response. The program is supported by nonclinical data showing

UroGen gets FDA IND clearance for bladder cancer virus therapy

Wed, 08 Jul 2026 08:02:17 -0400

UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer

Wed, 08 Jul 2026 08:00:00 -0400

FDA clearance enables initiation of a planned Phase 1 clinical study evaluating local intravesical administration of UGN-501, with patient enrollment expected to begin in Q4 2026
UGN-501 is a differentiated investigational next-generation oncolytic virus designed to combine direct tumor cell destruction with anti-tumor immune activation

PRINCETON, N.J., July 08, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that the U.S. Food and Drug Administration (FDA) cleared the Company's Investigational New Drug application (IND)

UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer

Wed, 08 Jul 2026 08:00:00 -0400

FDA clearance enables initiation of a planned Phase 1 clinical study evaluating local intravesical administration of UGN-501, with patient enrollment expected to begin in Q4 2026
UGN-501 is a differentiated investigational next-generation oncolytic virus designed to combine direct tumor cell destruction with anti-tumor immune activation

Form 4 UroGen Pharma Ltd. For: Jun 22 Filed by: Schoenberg Mark

Wed, 24 Jun 2026 10:23:00 -0400

si-local-file:///var/storage/secattach/20260624/26683683.html

Form 4 UroGen Pharma Ltd. For: Jun 22 Filed by: Schoenberg Mark

Wed, 24 Jun 2026 10:23:00 -0400

si-local-file:///var/storage/secattach/20260624/26683683.html

Form 4 UroGen Pharma Ltd. For: Jun 22 Filed by: Wildman Daniel George

Wed, 24 Jun 2026 10:04:00 -0400

si-local-file:///var/storage/secattach/20260624/26683557.html

Form 4 UroGen Pharma Ltd. For: Jun 22 Filed by: Wildman Daniel George

Wed, 24 Jun 2026 10:04:00 -0400

si-local-file:///var/storage/secattach/20260624/26683557.html

Form 4 UroGen Pharma Ltd. For: Jun 22 Filed by: Robinson James A. Jr.

Wed, 24 Jun 2026 10:03:00 -0400

si-local-file:///var/storage/secattach/20260624/26683550.html

Form 4 UroGen Pharma Ltd. For: Jun 22 Filed by: Robinson James A. Jr.

Wed, 24 Jun 2026 10:03:00 -0400

si-local-file:///var/storage/secattach/20260624/26683550.html

Form 4 UroGen Pharma Ltd. For: Jun 22 Filed by: Holden Stuart

Wed, 24 Jun 2026 10:01:00 -0400

si-local-file:///var/storage/secattach/20260624/26683544.html

Form 4 UroGen Pharma Ltd. For: Jun 22 Filed by: Holden Stuart

Wed, 24 Jun 2026 10:01:00 -0400

si-local-file:///var/storage/secattach/20260624/26683544.html

Form 4 UroGen Pharma Ltd. For: Jun 22 Filed by: BUTITTA CYNTHIA M

Wed, 24 Jun 2026 10:00:00 -0400

si-local-file:///var/storage/secattach/20260624/26683508.html

Form 4 UroGen Pharma Ltd. For: Jun 22 Filed by: BUTITTA CYNTHIA M

Wed, 24 Jun 2026 10:00:00 -0400

si-local-file:///var/storage/secattach/20260624/26683508.html